Natural history of venous thromboembolism

被引:804
作者
Kearon, C [1 ]
机构
[1] Henderson Gen Hosp, McMaster Clin, Hamilton, ON L8V 1C3, Canada
基金
美国国家卫生研究院;
关键词
embolism; epidemiology; risk factors; thrombosis; veins;
D O I
10.1161/01.CIR.0000078464.82671.78
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Most deep vein thromboses (DVTs) start in the calf, and most probably resolve spontaneously. Thrombi that remain confined to the calf rarely cause leg symptoms or symptomatic pulmonary embolism ( PE). The probability that calf DVT will extend to involve the proximal veins and subsequently cause PE increases with the severity of the initiating prothrombotic stimulus. Although acute venous thromboembolism (VTE) usually presents with either leg or pulmonary symptoms, most patients have thrombosis at both sites at the time of diagnosis. Proximal DVTs resolve slowly during treatment with anticoagulants, and thrombi remain detectable in half of the patients after a year. Resolution of DVT is less likely in patients with a large initial thrombus or cancer. About 10% of patients with symptomatic DVTs develop severe post-thrombotic syndrome within 5 years, and recurrent ipsilateral DVT increases this risk. About 10% of PEs are rapidly fatal, and an additional 5% cause death later, despite diagnosis and treatment. About 50% of diagnosed PEs are associated with right ventricular dysfunction, which is associated with a approximate to5-fold greater in-hospital mortality. There is approximate to50% resolution of PE after 1 month of treatment, and perfusion eventually returns to normal in two thirds of patients. About 5% of treated patients with PE develop pulmonary hypertension as a result of poor resolution. After a course of treatment, the risk of recurrent thrombosis is higher (ie, approximate to 10% per patient-year) in patients without reversible risk factors, in those with cancer, and in those with prothrombotic biochemical abnormalities such as antiphospholipid antibodies and homozygous factor V Leiden.
引用
收藏
页码:I22 / I30
页数:9
相关论文
共 141 条
  • [1] Agnelli G, 2000, ORTHOPEDICS, V23, pS643
  • [2] MORTALITY IN PATIENTS TREATED FOR PULMONARY-EMBOLISM
    ALPERT, JS
    SMITH, R
    CARLSON, CJ
    OCKENE, IS
    DEXTER, L
    DALEN, JE
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1976, 236 (13): : 1477 - 1480
  • [3] [Anonymous], 1990, CHEST, V97, P528
  • [4] [Anonymous], 1994, BMJ
  • [5] BARRITT DW, 1960, LANCET, V1, P1309
  • [6] CURRENT STATUS OF PULMONARY THROMBOEMBOLIC DISEASE - PATHO-PHYSIOLOGY, DIAGNOSIS, PREVENTION, AND TREATMENT
    BELL, WR
    SIMON, TL
    [J]. AMERICAN HEART JOURNAL, 1982, 103 (02) : 239 - 262
  • [7] Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
    Bergqvist, D
    Agnelli, G
    Cohen, AT
    Eldor, A
    Nilsson, PE
    Le Moigne-Amrani, A
    Dietrich-Neto, F
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (13) : 975 - 980
  • [8] A 30-YEAR SURVEY OF PULMONARY-EMBOLISM VERIFIED AT AUTOPSY - AN ANALYSIS OF 1274 SURGICAL PATIENTS
    BERGQVIST, D
    LINDBLAD, B
    [J]. BRITISH JOURNAL OF SURGERY, 1985, 72 (02) : 105 - 108
  • [9] Biguzzi E, 1998, THROMB HAEMOSTASIS, V80, P575
  • [10] BLACKMON JR, 1970, JAMA-J AM MED ASSOC, V214, P2163